近日,科望医药(Elpiscience Biopharmaceuticals, Inc.)再次递表港交所,拟在港交所主板上市,中信证券为独家保荐人。此前,公司曾多次寻求上市,2021年,公司曾以保密方式向美国证监会提交上市申请文件,但鉴于美国的市场状况,最终决定于2022年撤回拟议美国上市的申请;2024年6月,公司递表港交所。科望医药成立于2017年,是一家致力于在全球范围内利用新一代疗法创新...
Source Link近日,科望医药(Elpiscience Biopharmaceuticals, Inc.)再次递表港交所,拟在港交所主板上市,中信证券为独家保荐人。此前,公司曾多次寻求上市,2021年,公司曾以保密方式向美国证监会提交上市申请文件,但鉴于美国的市场状况,最终决定于2022年撤回拟议美国上市的申请;2024年6月,公司递表港交所。科望医药成立于2017年,是一家致力于在全球范围内利用新一代疗法创新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.